PHARMACOTHERAPEUTIC EVOLUTION OF ANTITUBERCULOSIS DRUG-A REVIEW
Journal Title: WORLD JOURNAL PHARMACY AND PHARMACEUTICAL SCIENCE - Year 2018, Vol 7, Issue 12
Abstract
Tuberculosis is a cosmopolitan human lung infection caused by Mycobacterium tuberculosis. It represents one of the main causes of death worldwide. The therapeutic management of this disease by antituberculosis drugs faces several obstacles such as low adherence, the long duration of treatment, adverse effects of the drugs and the existance of the latent tuberculosis caused by dormant bacilli. Furthermore, the drug treatment of co-infection HIV and tuberculosis resistant is in a situation of therapeutic deadlock. Therefore, it seemed worthwhile to make an inventory of antituberculosis drugs and have a better understanding of future therapeutic options. This study highlighted the existance of many "doubtful" non-drug treatments proposed to treat tuberculosis before the discovery of modern tuberculosis chemotherapy. Some of them suggested prayers, incantations (heal power of kings), or a simple rest combined with a balanced diet. Others less gentle methods such as the injection of air into the lungs recommended surgical treatments like thoracoplasty. Various treatment based on gold salts, cod liver oil or the sanatorium cures were also tested. The discovery of streptomycin in the 1940, was the beginning of the current anti-tuberculosis therapy. Indeed, research aimed at finding an alternative treatment, to overcome the Streptomycin resistance, led to the introduction in therapy of many other antituberculosis like Para-aminosalicylic acid (1944), Isoniazid (1952), the ethambutol (1957), Rifampicin (1967), the pyrazinamide (1980) and fluoroquinolones (1982). Moreover, in order to shorten the duration of treatment and to limit the the emergence and spread of resistance, combination of antituberculous drugs has been proposed and the treatment of tuberculosis has evolved from monotherapy to quadruple today. In addition, to deal with the appearance of poly-resistant strains and overcome the drawbacks existing tuberculosis drugs, research is underway to identify new biological targets and to develop antituberculosis of the future.
Authors and Affiliations
Ouattara Mahama
Keywords
Related Articles
- EP ID EP628184
- DOI -
- Views 143
- Downloads 0
EVALUATION OF DRUG TREATMENT OPTIONS FOR ALZHEIMER'S DISEASE - A REVIEW OF EARLIER STUDIES
Therapeutic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine and rivastigmine. A review of the evidence by searching MEDLINE, Embase, The Cochrane Library and the Internatio...
STATISTICAL STUDY OF STABILITY CONSTANTS FOR SOME AZO IMINE PHENOLIC DYES THEORETICALLY BY USING PARAMETERIZED METHOD (PM3)
In this study, the study included the calculation of nine Azo imine phenolic dyes, which included nine Schiff bases. The parameters of the stability of the compounds under study were calculated at absolute temperatures (...
ANTIDIABETIC AND HYPOLIPIDEMIC EFFECT OF ASPARAGUS RACEMOSUS IN ALLOXAN INDUCED DIABETES IN RATS.
The Asparagus racemosus was evaluated for its antidiabetic activities and hypolipidemic activity against alloxan induced hyperglycemia in rats. Thirty rats were used divided into 2 groups, normal control: Composed from 1...
THE QUANTITATIVE SERUM BRCA1AND SERUM ZINC AS A NOVEL BIOMARKERS WITH THE CORRELATIONS BETWEEN THEM IN THE FAMILIAL BREAST CANCER PATIENTS IN IRAQ.
Background: Breast cancer is the most common malignant tumor in women worldwide and in Iraq. Many studies show BRCA1 and zinc are the substances that expressed significantly in tissues or serum specimens from a genetical...
CHRONIC MYELOID LEUKEMIA PATIENT WITH ISOLATED CENTRAL NERVOUS SYSTEM BLAST CRISIS
The first therapeutic choice in Chronic Myeloid Leukemia (CML) is imatinib mesylate, a potent inhibitor of BCR / ABL tyrosine kinase. The blood brain barrier is poorly penetrated so that therapeutic concentrations in the...